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The CD40–CD40L dyad is an immune checkpoint regulator that promotes both innate 
and adaptive immune responses and has therefore an essential role in the development 
of inflammatory diseases, including multiple sclerosis (MS). In MS, CD40 and CD40L 
are expressed on immune cells present in blood and lymphoid organs, affected resident 
central nervous system (CNS) cells, and inflammatory cells that have infiltrated the CNS. 
CD40–CD40L interactions fuel the inflammatory response underlying MS, and both 
genetic deficiency and antibody-mediated inhibition of the CD40–CD40L dyad reduce 
disease severity in experimental autoimmune encephalomyelitis (EAE). Both proteins are 
therefore attractive therapeutic candidates to modulate aberrant inflammatory responses 
in MS. Here, we discuss the genetic, experimental and clinical studies on the role of 
CD40 and CD40L interactions in EAE and MS and we explore novel approaches to 
therapeutically target this dyad to combat neuroinflammatory diseases.
Keywords: CD40, CD40L, multiple sclerosis, experimental autoimmune encephalomyelitis, inflammation, tumor 
necrosis factor receptor-associated factors
iNTRODUCTiON
Multiple sclerosis (MS), a chronic inflammatory, demyelinating disease of the central nervous system 
(CNS), affects approximately 2.5 million people worldwide and is the most common cause of non-
traumatic neurological disability in young adults (1). MS can be subdivided in different disease 
courses, including relapsing remitting MS (RRMS), secondary progressive MS (SPMS), and primary 
progressive MS (PPMS) (2). At disease onset, 85% of the patients have RRMS, which is characterized 
by acute attacks (relapses) followed by a period of partial or full recovery (remission) of the symptoms. 
Approximately 50% of these patients will subsequently develop SPMS. Although the etiology of MS 
is unknown, the disease is characterized by dynamic inflammatory lesions, consisting of activated 
T cells, B cells, macrophages and CNS-resident cells that eventually cause severe CNS tissue damage 
resulting in neurological deficits (3–6). Glucocorticoids are commonly used to inhibit the inflam-
matory response causing relapses. Although these drugs promote a faster recovery, there are no 
long-term neuroprotective effects (7, 8). In RRMS, reduced frequency of relapses and inhibition of 
disease progression is observed upon treatment with disease modifying drugs, including interferons, 
2Aarts et al. The CD40–CD40L Dyad in MS
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1791
glatiramer acetate, sphingosine-1-phosphate receptor modula-
tors and monoclonal antibodies directed against α4-integrin 
(natalizumab), CD52 (alemtuzumab), CD25 (daclizumab), and 
CD20 (ocrelizumab, ofatumumab) (7). These agents success-
fully extended the treatment strategies for RRMS, but disease 
modifying drugs lacked efficacy in progressive MS and may have 
potentially severe adverse effects including cytopenias, infec-
tious diseases, and progressive multifocal leukoencephalopathy 
(9–12). Identification of additional therapeutic targets, especially 
for progressive MS, is therefore a widely recognized scientific goal 
with great clinical implications.
CD40 is a membrane-bound costimulatory protein and is a 
member of the tumor necrosis factor receptor (TNFR) family. 
CD40 is constitutively expressed by B cells and dendritic cells, but 
upon cell activation the protein is broadly expressed on hemat-
opoietic cells, including T  cells, monocytes and macrophages, 
but also on non-hematopoietic cells, such as endothelial cells 
(ECs) and CNS resident cells. The classical ligand for CD40 is 
the tumor necrosis factor (TNF) family member CD40 ligand 
(CD40L), which is expressed on both T cells and platelets. During 
inflammation CD40L is also expressed on B cells, dendritic cells, 
monocytes, macrophages, EC, and CNS resident cells, amongst 
others. CD40-mediated signaling depends on adaptor molecules, 
the TNF-receptor-associated factors (TRAFs) that bind to the 
cytoplasmic tail of CD40 and can activate multiple signaling 
cascades dependent on the TRAF family member that binds and 
the cell-type that is activated. The CD40 cytoplasmic domain 
has a proximal TRAF-6 binding site and a more distal TRAF-
2/3/5 binding site (13). The CD40–CD40L dyad is an immune 
checkpoint regulator that promotes both humoral and cellular 
immune responses by regulating the inflammatory phenotype of 
immune and non-immune cells. Genetic and antibody-mediated 
inhibition of CD40 or CD40L successfully reduced disease bur-
den in experimental models of atherosclerosis, Crohn’s disease, 
psoriasis, rheumatoid arthritis (RA), and experimental autoim-
mune encephalomyelitis (EAE) (14).
Experimental studies identified the CD40–CD40L dyad as a 
potent therapeutic target in MS (15–21). A pilot study with anti-
CD40L mAb IDEC-131 in MS patients was successful, which led 
to the launch of a phase II trial. Unfortunately, this trial was halted 
after a case of severe thromboembolism in an IDEC-131 trial in 
Crohn’s disease patients (22). Clinical applicability of antibody-
mediated blockage of CD40 is compromised by the risk of severe 
immunosuppression. Interestingly, recent insights in the down-
stream CD40 signaling pathways identified novel possibilities to 
inhibit the CD40–CD40L dyad without these side effects (13, 23).
In this review, we discuss genetic, experimental, and clinical 
studies on the role of CD40 and CD40L in the neuroinflamma-
tory response underlying MS and we explore novel strategies that 
may eventually overcome the current limitations of antagonizing 
the CD40–CD40L dyad in MS.
eXPReSSiON OF CD40L DURiNG MS
Our knowledge on the expression of CD40L and CD40 in MS 
is based on postmortal human studies and on reports from 
studying EAE, a widely used animal model of MS. In this model, 
neuroinflammation is initiated by T cells. However, for demyeli-
nation monocyte-derived macrophages, opsonizing antibodies 
and complement have been shown to play an essential role (24).
T Cells
In order to initiate a proper T cell-mediated immune response, 
cell–cell interactions between T  cells and antigen-presenting 
cells (APCs), such as B cells, macrophages, and dendritic cells are 
required. Three distinct signals are needed for T cell activation: 
binding of the T  cell receptor with the MHC class II complex 
on APCs is the first signal, the second signal is generated by 
costimulatory molecules, and the third signal originates from 
cytokines. CD40L expressing T  cells can activate resting APCs 
via interaction with their CD40 receptors. Upon activation the 
APCs will upregulate cytokine receptors and other costimulatory 
molecules (25).
Both CD4+ and CD8+ T cells are abundantly present in MS 
lesions. During immune activation, both T  cell subsets can 
express CD40L, however, in MS CD40L expression is only 
detected on CD4+ T cells, and not CD8+ T cells (26). CD40L is 
not detected in the healthy CNS, nor in the CNS of patients with 
other neurodegenerative disorders like Alzheimer’s Disease (15), 
suggesting that infiltrated CD40L+ T cells are the driver of CD40-
mediated inflammation in MS. Infiltrated CD40L+ T cells induce 
activation of the various CD40-expressing cells (27) (Figure 1A). 
Likewise, in murine relapsing-remitting EAE, CD40L-expressing 
T cells infiltrate the CNS as early as day 4 postimmunization, and 
the number of CD40L+ T cells increased in the acute phase and 
peaked during remission, indeed suggesting that CD40L drives 
the initial phases of neuroinflammation (28).
Soluble CD40L (sCD40L)
Besides membrane-bound CD40L, CD40L also exists as a soluble 
protein: sCD40L, which is mainly derived from activated platelets 
(95%) and T cells (5%) (29, 30). After cleavage from the platelet 
surface, sCD40L remains trimeric and can bind to integrin αIIbβ3 
on platelets or the CD40 receptor, which induces the expression 
of inflammatory mediators, such adhesion molecules, tissue fac-
tor, and chemokines (30).
Multiple population studies have demonstrated that serum 
sCD40L concentrations were increased in MS patients with 
active disease compared to healthy controls (5.65  ±  2.87 vs. 
0.14 ±  0.12  ng/mL, p <  0.001) or patients with inactive MS 
(5.65 ± 2.87 vs. 0.64 ± 0.30 ng/mL, p < 0.001) (31, 32). A similar 
increase of sCD40L was detected in the CSF of MS patients com-
pared to patients suffering from other inflammatory or neurologi-
cal diseases (38.5 vs. 4.8 pg/mL, p < 0.002; SD not mentioned in the 
manuscript) (33). Although serum sCD40L concentrations, but 
not CSF sCD40L concentrations, positively correlated (Kendall 
tau-b  =  0.29, p  =  0.044) with the CSF/serum albumin ratio 
(“Qalb”), an indicator of blood-brain barrier permeability (33), 
it is currently unknown whether sCD40L directly contributes to 
BBB breakdown. Interestingly, serum concentrations of sCD40L 
decreased upon treatment with Glatiramer acetate (copaxone) 
(34), IFN-β (35), or natalizumab (36), suggesting that sCD40L 
can be used as a biomarker to monitor the effectiveness of these 
therapies.
FiGURe 1 | The critical role of the CD40 ligand (CD40L)–CD40 dyad in the inflammatory response underlying multiple sclerosis (MS)/experimental autoimmune 
encephalomyelitis (EAE). (A) During MS/EAE, the number of CD40L+CD4+ T cells in the peripheral blood and central nervous system (CNS) increases. Besides a 
membrane bound form, CD40L also exists as soluble trimer, which is mainly derived from platelets. CD40L interacts with CD40 on endothelial cells (ECs) and 
circulating monocytes and B cells. Within the CNS, T cells activate CD40+ macrophages, microglia, B cells, and plasma cells. (B) CD40L-mediated activation of 
CD40 on EC results in the expression of adhesion molecules, including VCAM, ICAM, and E-selectin, which promotes the recruitment of inflammatory cells to the 
CNS. CD40L also induces B cell activation, characterized by CD69 expression, and proliferation. Furthermore, the antigen presenting capacity of B cells is improved 
as a result of increased MHC class II, CD54, CD80, and CD86 expression. CD40L also promotes the secretion of proinflammatory cytokines by circulating 
monocytes and macrophages and microglia in the CNS. Thus, the CD40L–CD40 dyad critically regulates both adaptive and innate immune responses.
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In contrast to these results, a large cohort study with 833 MS 
patients showed decreased levels of sCD40L in patients with 
inactive MS compared to healthy individuals (86.3  ±  9.3 vs. 
54.3 ± 5.4 pg/mL, p < 0.001) (37). Several factors may contribute 
to these conflicting findings, including the use of antiplatelet 
drugs, such as cyclooxygenase inhibitors or adenosine diphos-
phate receptor inhibitors, which limit the release of sCD40L 
from activated platelets (29). Importantly, the use of these agents 
has not been reported in the population studies. In addition, a 
circadian rhythm in serum sCD40L levels has been observed 
in patient suffering from myocardial infarction, sCD40L levels 
were 41.5% higher in samples obtained at 9  p.m. compared to 
samples drawn at 2 a.m., possibly due to diurnal fluctuations in 
proteinase levels (38). Whether a similar circadian rhythm is 
present in MS patients is currently unknown. Finally, differences 
in blood sample handling may affect serum sCD40L levels, as low 
temperatures limit the ex vivo release of sCD40L from platelets 
(29). Carefully monitoring of these factors in future studies is 
required to fully elucidate the role of sCD40L in MS.
eXPReSSiON OF CD40 DURiNG MS
Macrophages and Microglia
Autopsy studies in MS patients revealed that monocytes, mac-
rophages and activated microglia are the main cell types express-
ing CD40 in the CNS (15). Microglia in a resting state show low 
or no CD40 expression, while ~45% of the activated microglia 
and ~73% of recruited peripheral macrophages express CD40 
during EAE (39). Macrophages form a functionally heterogene-
ous population, with proinflammatory M1 macrophages and 
anti-inflammatory M2 macrophages representing the extremes 
of a spectrum that is present in vivo (40). CD40 is an M1 marker 
for perivascular macrophages, activated microglia and myelin-
loaded macrophages in MS lesions and its expression is associated 
with the coexpression of other M1-markers, such as CD86, CD64, 
and CD32. CD40L-induced activation of these cells results in the 
secretion of M1-associated cytokines and chemokines, including 
interleukin (IL)-1, IL-6, IL-12, IL-18, and TNF-α (41–43), which 
fuels the ongoing inflammation in the CNS (Figure 1B) (44–47). 
However, 70% of the CD40+ cells also express M2 markers, 
including CD163 and CD206, suggesting that a mixed M1/M2 
phenotype exists in MS lesions (48). The abundant expression of 
CD40 on mononuclear cells in perivascular infiltrates was also 
found in the brain of marmoset monkeys (Callithrix jacchus) 
with acute EAE (24). In murine relapsing-remitting EAE, CD40 
expressing cells infiltrate the CNS as early as day 4 postimmuniza-
tion and the numbers of CD40+ cells peaked in the acute and 
relapsing phases of the disease and decreased during remission 
(28). The amount of CD40 present in the CNS correlated with 
the expression of the inflammatory cytokines IL-12, IFN-γ, and 
TNF-α (28). Correspondingly, in the mouse spinal cord CD40 
was abundantly expressed by monocytes and monocyte-derived 
macrophages (17). The expression of CD40 in the CNS found in 
mice and marmoset monkeys suggests that there is HLA class 
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II-restricted antigen presentation, and that effector functions 
of CD40 expressing macrophages are triggered by CD40L-
expressing activated CD4+ T cells (17, 24). In vitro, interactions 
between T cells and macrophages can stimulate the production 
of proinflammatory cytokines, nitric oxide, and matrix metal-
loproteinases, which are all components that play a role in the 
immunopathogenesis of MS and other chronic inflammatory 
diseases (17).
B Cells
In order to initiate a humoral immune response, CD40L present 
on activated CD4+ T  cells needs to interact with the CD40 
receptor on antigen activated B cells. During this response, high 
titers of isotype-switched, high affinity antibodies are generated 
by the B cells and germinal centers (GCs) are formed (49, 50). 
Furthermore, CD40–CD40L signaling between follicular helper 
CD4+ T cells (TFH) and GC B cells is required for the formation 
of memory B cells, antibody-secreting plasma cells and the main-
tenance of GC (51, 52). The number of circulating CD40+CD20+ 
B cells did not differ between MS patients and controls; however, 
the density of CD40 on these cells was increased, which may have 
several effects on B cell function (53). First, CD40 activation on 
both naïve (CD19+CD27−) B cells and memory (CD19+CD27+) 
B  cells results in the activation of these cells, characterized by 
CD69 expression (54). Second, the proliferative response of both 
naïve and memory B  cells is increased upon CD40 activation 
(55). Third, the antigen presenting capacity of B  cells was also 
affected as upon ligation of CD40 by CD40L, B  cells from MS 
patients exhibited increased expression of MHC class I and II, 
CD54, CD80 and CD86, which promoted the activation and pro-
liferation of T cells, especially CD4+ T cells. These CD4+ T cells 
subsequently induced the proliferation of CNS-antigen specific 
CD8+ T cells, at least in vitro (54, 56).
NF-κB and MAPKs (P38, ERK, and JNK) are essential com-
ponents of signaling pathways downstream of CD40 binding in 
B cells. Following CD40 stimulation, memory and naive B cells 
from MS patients showed a significantly higher level of NF-κB 
activation, reflected by increased levels phosphorylated p65, 
compared with healthy controls (57). Treatment with glatiramer 
acetate (Copaxone) reduced the phosphorylation of p65 in B cells 
of RRMS patients to levels observed in healthy individuals. These 
results suggest that reducing CD40-mediated activation of the 
canonical NFkB pathways may be a common mechanism by 
which some existing treatments limit inflammation in MS (57).
In recent years, a novel subset of regulatory B cells, which 
secrete anti-inflammatory cytokines such as IL-10 and TGF-β, 
has been described (58). CD40-induced activation of these 
cells reduced inflammation and disease severity in a murine 
model of systemic lupus erythematosus in an IL-10-dependent 
manner (59). However, Michel et  al. reported that both the 
frequency and function of regulatory B cells was not affected 
in MS patients, specifically, CD40L-induced cytokine secretion 
was unaffected, suggesting that a similar mechanism is not 
present in MS (60).
The clinical success of B cell depleting therapies implicates an 
important role for these cells in the pathogenesis of MS. Indeed, 
ectopic B  cell follicles have been detected in the meninges of 
patients with progressive MS, immunoglobulin depositions 
are present in MS lesions and oligoclonal immunoglobulins 
are detected in the CSF of 90% of the patients (61). Although 
the pathologic effect of these autoantibodies is incompletely 
understood, several autoantigens have been detected, including 
MOG, neurofascin, sperm-associated antigen 16 (SPAG16), 
contactin-2 and inward-Rectifying Potassium Channel 
(KIR4.1) (62). Interestingly, the CD40–CD40L dyad has a criti-
cal role in B cell biology, as it regulates antibody production, 
immunoglobulin isotype switching and B cell follicle formation, 
accordingly, antibody-mediated inhibition of CD40 reduced 
anti-MOG antibody production in non-human primates sub-
jected to EAE (20). Whether CD40 signaling plays a relevant 
role in the generation of autoantibodies in the context of MS is 
currently unknown.
CD40 expression on T Cells
CD40 expression is mostly described on APCs, but CD4+ and 
CD8+ T  cells can also express low levels of CD40 mRNA that 
increase after activation. Effector T cells deficient for CD40 have 
poor capacity to proliferate, and antigen stimulated cytokine 
secretion during the primary immune response and in the mem-
ory phase is as low as that of naive T cells. Priming with CD4+ 
T cells did not increase the proliferation and cytokine secretion 
capacity of CD40-deficient T cells, demonstrating that CD4 help 
to CD8+ T  cells requires interactions with CD40 expressed by 
CD8+ T cells (63). The role of CD8+ T cells in MS and EAE is not 
completely understood and is rather controversial with evidence 
for both a pathogenic and a regulatory function (64). The role of 
CD4+ T cells expressing CD40 (CD40+CD4+ T cells) in EAE is 
recently investigated. CD40+CD4+ T cells are found in lesions in 
the CNS and stimulate a more severe EAE disease development 
than conventional CD4+ T cells (65). Adoptive CD40+CD4+ T cell 
transfer from EAE-induced donors transfers EAE without further 
in vitro expansion and without requirement of an EAE inducing 
procedure to the recipient animals. Coinjection of the CD40+CD4+ 
donor T cells with CFA in the recipient animals results in a more 
severe disease outcome (65), indicating that in addition to the 
specific T cell response to CNS antigen, a general activation of the 
immune system is necessary to induce severe disease. Moreover, 
this suggests that any event leading to CD40+CD4+ T cell expan-
sion might result in susceptible individuals.
endothelial Cells
In addition to immune cells, 25% of brain EC constitutively 
express CD40 in situ and in vitro and the expression is further 
increased by inflammatory stimuli (48, 66–68). Activation of 
endothelial CD40 by CD40L induces the expression of the adhe-
sion molecules E-selectin, VCAM-1, and ICAM-1 (Figure 1B), 
which facilitates the migration of monocytes and CD4+ T and 
CD8+ T cells into the CNS. Brain ECs also induce T cell activation 
and proliferation via MHC-II-dependent antigen presentation 
and CD40-mediated costimulation (66). Thus, CD40–CD40L-
mediated interactions between EC and immune cells promote 
CNS inflammation by facilitating transmigration of leukocytes 
across the BBB and subsequently inducing T cell activation and 
proliferation (67).
5Aarts et al. The CD40–CD40L Dyad in MS
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1791
Resident CNS Cells
CD40 is also expressed on other resident CNS cell types like 
astrocytes and neurons. Astrocyte CD40 induces the secretion 
of proinflammatory cytokines and chemokines, which trigger an 
autocrine activation of these cells that aggravate EAE (69). CD40 
is constitutively expressed on neurons (70). CD40L-induced acti-
vation of primary cultured neuronal cells results in activation of 
p44/42 MAPK signaling pathways, and increases neurofilament 
expression, a marker of neuronal differentiation. In addition, 
CD40 has a critical role in neuronal survival as neuronal cell 
injury induced by serum withdrawal can be rescued by CD40 
ligation in wild-type neurons, but injury could not be reduced 
by CD40 ligation in CD40-deficient neurons. These in vitro find-
ings are further supported by observations in aged Cd40−/− mice. 
Examination of the brain of CD40-deficient mice showed that at 
older age (16 months) CD40 deficiency results in decreased neu-
rofilament expression, neuronal dysmorphology, reduced brain 
weights, and increased TUNEL reaction, indicating increased 
presence of apoptotic cells (70). Additionally, phenotypic analy-
sis of Cd40−/− mice showed that CD40 regulates growth from 
excitatory and inhibitory neuron dendrites (71). In conclusion, 
neuronal CD40 has an important role in neuronal development, 
maintenance, and survival.
expression of CD40–CD40L on Circulating 
immune Cells in MS
In addition to the local alterations in the CNS discussed above, 
the systemic immune system is also affected in MS (1). The 
expression of CD40 and CD40L on peripheral blood monocytes, 
especially the CD16+ proinflammatory subset, is increased in 
MS patients, reflecting the higher activation status of these cells 
(53, 72–74). Besides inflammatory cytokines, monocytes also 
produce protective anti-inflammatory mediators upon CD40L-
induced activation such as the neurotrophins BDNF, NT3, and 
NGFβ (39). Interestingly, this protective response is reduced in 
monocytes from MS patients, but restored upon IFNβ treatment 
(75–77).
Circulating CD40L+ CD4+ T cells and CD40L+ CD8+ T cells are 
also more abundant in MS patients compared to healthy controls 
(53, 78). Upon in vitro CD3-induced reactivation, CD4+ T cells 
from MS patients expressed more CD40L and produced increased 
levels of inflammatory mediators, compared to T cells from healthy 
controls, suggesting that CD40L is especially expressed by acti-
vated proinflammatory T cells (79). Interestingly, IFNβ reversed 
the increased expression of CD40L on CD4+ T cells (53, 80).
Taken together, during neuroinflammation, CD40L+ CD4+ 
T  cells infiltrate the CNS and activate CD40+ monocytes, 
macrophages, B cells, ECs, and other CNS resident cells, which 
propagates the ongoing inflammatory response and aggravates 
lesion development (Figures 1A,B). Consequently, two strategies 
can be applied to therapeutically target the CD40–CD40L dyad 
in MS; (1) inhibition of CD40 on resident and immune cells; (2) 
inhibition of CD40L on T cells. While the role of CD40L-induced 
activation of CD40+ cells in immunity and inflammation is well 
known, only limited data exist on the reciprocal activation of 
CD40L+ cells. The intracellular domain of CD40L does not contain 
any signaling motifs, however upon activation its transmembrane 
domain associates with lipid rafts, thereby inducing AKT and p38 
MAPKs pathways and the subsequent production of IL-2, based 
on in vitro experiments (81). Additionally, this may promote IL-4, 
IL-10, TNF-α, and IFN-γ production (82). However, the patho-
physiological relevance of the reciprocal activation of CD40L+ 
cells in MS or other inflammatory diseases has not been explored 
and requires further attention as it may result in the identification 
of novel therapeutic targets.
CD40 SiNGLe-NUCLeOTiDe 
POLYMORPHiSMS (SNPs) AND MS
Genome-wide association studies have identified a correlation 
between SNPs in immune related loci, including the CD40 
locus, and the incidence of MS (83). In particular, the SNP 
rs1883832C-  >  T in the CD40 gene was associated with an 
increased risk for MS. Compared to rs1883832CC individuals, 
heterozygous rs1883832CT and homozygous rs1883832TT indi-
viduals had a 1.5-fold and 2.5-fold increased risk for MS, respec-
tively (84). Counterintuitively, the high-risk allele was associated 
with a 45.5% decreased expression of CD40 mRNA in an in vitro 
translation/transcription system (85, 86). A second CD40 SNP 
(rs6074022T- > C) was also associated with a minor decrease in 
the expression of CD40 mRNA in whole blood RNA from MS 
patients (87–89). Thus, at least two high risk SNPs are associated 
with a decreased expression of CD40, which seems contradictory 
and requires further attention, as in vivo studies have established 
the proinflammatory role of CD40 in neuroinflammation, as 
discussed below. In RA and Graves’ disease CD40 rs1883832 is 
associated with reduced CD40 expression and disease protection. 
These findings are in line with the role of CD40 as a costimulator 
in T  cell activation supporting the autoimmune inflammatory 
process (86). How to explain the increased risk for MS upon 
decreased CD40 mRNA expression is so far unclear. Until now, 
no polymorphisms of the CD40L gene have been associated with 
MS (84).
PROMiSiNG THeRAPeUTiC POTeNTiAL 
OF THe CD40L–CD40 DYAD FOR eAe  
AND MS
Several EAE studies in mice and non-human primates showed 
that the CD40–CD40L signaling pathway is an interesting 
target to reduce incidence and severity of neuroinflammation. 
Combination therapies can even further increase treatment 
efficiency. A discussion of this research is described here.
Genetic Deficiency of CD40 or CD40L  
in Mouse eAe
Both CD40- and CD40L-knock-out mice do not develop EAE 
after immunization. CD40–CD40L interactions are required for 
the B7.1 and B7.2 expression on APCs, essential for T cell activa-
tion. Lack of costimulation through B7.1 and B7.2 may result in a 
reduction of secondary signaling and prevention of T cell activa-
tion, possibly responsible for protection of CD40L-deficient mice 
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from EAE (16). Experiments with Cd40−/− mice showed that in the 
absence of CD40, T cells both enter the CNS and induce disease. 
This suggests that activated T cell trans-migration through the 
endothelial BBB does not require CD40 (90). However, CD40 is 
necessary for Th1 cell activation as in the presence of CD40, there 
is an earlier entrance of Th1 cells into the CNS and more severe 
induction of disease (90). CD40 on peripheral hematopoietic cells 
is known to be pivotal to the development of autoimmunity (25). 
By using bone marrow (BM) chimeric mice, Becher et al. showed 
that lack of expression of CD40 on CNS-resident microglia also 
diminishes EAE severity and reduces the amount of leukocyte 
infiltration into the CNS (91). Reduced microglial expression of 
CD40 did not affect peripheral T cell priming or recall responses. 
Encephalitogenic T  cells could not elicit the expression of 
chemokines in a CNS environment in which parenchymal micro-
glia were CD40 depleted. So, outside of the systemic immune 
compartment CD40 increases organ-specific autoimmunity and 
within the CNS CD40 expressing cells regulate the EAE develop-
ment in BM chimeric mice (91).
Antibody-Mediated inhibition of CD40L in 
Mouse eAe
Treatment of EAE-induced mice with an antagonistic anti-CD40L 
mAb (MR1) during disease induction (days 0–4) completely 
prevented development of disease (15). Treatment during days 
4–8 and days 7–11 after induction reduced disease burden by 80 
and 67%, respectively (15). Antibody treatment inhibited CNS 
inflammatory processes, as the number and size of CNS infiltrates 
of animals treated with anti-CD40L antibodies during EAE induc-
tion were strongly reduced compared to animals treated with an 
irrelevant antibody (17). Besides treatment at disease induction, 
EAE disease development and CNS inflammation were also 
blocked effectively by anti-CD40L antibody treatment of animals 
at the peak of acute disease and by treatment during remission 
(18). Interestingly, transient anti-CD40L blockade at the peak of 
the acute phase of R-EAE in SJL mice reduced clinical relapses 
by 80%, and in mice that did develop a relapse, the duration and 
severity was reduced as compared to control antibody treated 
animals (19). Short-term (4  days) treatment with anti-CD40L 
during EAE induction could prevent clinical disease and did not 
affect the long-term Th1/Th2 balance (92).
Mechanism of Disease Reduction upon 
Anti-CD40L Treatment
Myelin-specific T cells in anti-CD40L-treated mice subjected to 
EAE secreted little IFNγ but exhibited strongly enhanced levels of 
IL-4, compared to control treated mice (Figure 2A). Anti-CD40L 
mAb did not result in systemic tolerance of encephalitogenic 
T  cells (93) nor caused expansion of myelin-specific T  cells. 
However, treatment with anti-CD40L antibody at the peak of 
acute disease or during remission inhibited Th1 differentiation 
and effector function. While T  cell proliferation and secretion 
of the cytokines IL-2, IL-4, IL-5, and IL-10 were normal (18), 
antibody treatment strongly impaired IFN-γ production, 
delayed-type hypersensitivity responses against myelin peptide, 
and encephalitogenic effector cell activation (18, 93). Treatment 
with anti-CD40L antibody also reduced clinical disease expres-
sion in adoptive recipients of encephalitogenic T cells, suggesting 
involvement of CD40–CD40L interactions in their effector ability 
to activate CNS macrophages/microglia (18).
CD40–CD40L interactions between APCs and T cells results 
in IL-12 secretion, an essential cytokine for Th1 responses and 
EAE induction. This has led to the hypothesis that the protective 
effects of CD40L blockade in EAE can be overcome by IL-12 
administration. Mice cotreated with exogenous IL-12 and the anti-
CD40L antibody developed severe EAE and anti-IL-12 antibody 
treatment protected mice from EAE (94). However, the protein 
IL-12 consists of a p35 and a p40 subunit, the IL-12p40 subunit is 
shared by other cytokines. Il-12p40−/− mice are protected against 
EAE, but Il-12p35−/− mice develop severe EAE, verifying that the 
p40 subunit, and not IL-12 is critical for the development of EAE 
(95). IL-23, another cytokine containing the p40 subunit, has later 
been shown to play a critical role in the EAE disease development 
instead of IL-12 (96, 97). Whether the beneficial effect of CD40 
blockade in EAE is mediated through reduced levels of IL-23 is 
not yet investigated, and the role of CD40–CD40L interactions in 
IL-23 secretion is still unclear.
To investigate whether the mechanism of EAE inhibition 
by anti-CD40L mAb depends on its Fc effector interactions, 
Nagelkerken et al. compared an anti-CD40L mAb (produced in 
mammalian cells) with its a-glycosylated counterpart, which has 
strongly reduced FcγR binding and impaired complement binding 
activity. They found that both forms of the Ab have similar ability 
to inhibit clinical signs of EAE (98). Therefore, in the context of 
EAE, FcR interactions do not play a crucial role in the protective 
effect of anti-CD40L mAb (98). Activation of microglial cells is a 
multistep process and microglial cell CD40 expression facilitates 
EAE disease development. Activation of microglial cells at the 
onset of EAE is a process independent of CD40, and their activa-
tion is characterized by increased expression of CD45 and MHC 
class II. However, at the peak of disease, complete activation of 
microglial cells is dependent on their CD40 expression (39). 
These results show that in order to facilitate the progression of 
EAE clinical disease activation of microglial cells in the CNS is 
needed (39).
Anti-CD40 and CD40L Antibody Treatment 
in eAe in Non-Human Primates
As treatment of EAE-induced mice with anti-CD40L mAb 
effectively blocked clinical disease progression and CNS inflam-
mation (15, 17, 18), CD40L–CD40 interaction inhibiting experi-
ments were extrapolated to non-human primate models of EAE. 
Anti-CD40 mAb showed beneficial activities in a EAE model in 
non-human primates when administered early in disease develop-
ment (20) or after the onset of neuroinflammation (21). Inhibition 
of CD40–CD40L interactions was tested in marmoset monkeys 
with anti-human CD40 mAb (ch5D12), a chimeric antagonist. 
Severe clinical signs of EAE were observed in all placebo-treated 
monkeys, whereas in the ch5D12-treated group the animals did 
not develop disease symptoms at all. Postmortem analysis of 
the CNS showed that ch5D12 treatment resulted in a reduced 
lesion load (20). The same model was used to test the anti-human 
FiGURe 2 | Strategies to target the CD40 ligand (CD40L)–CD40L dyad in experimental autoimmune encephalomyelitis (EAE). (A) Antagonistic CD40L antibodies 
limit detrimental T cell responses in multiple sclerosis (MS) by decreasing IFNγ production, reducing myelin peptide-specific delayed-type hypersensitivity responses, 
and limiting in effector T cell formation. In addition, antibody treatment enhances the production of the Th2 cytokine interleukin (IL)-4. (B,C) A novel strategy to target 
the CD40L–CD40 axis in monocytes and macrophages during EAE. The CD40L–CD40–TRAF6 axis activates the transcription factor NF-κB, which subsequently 
induces an inflammatory monocyte/macrophage phenotype that aggravates EAE. Small molecule-mediated inhibition of the CD40–TRAF6 interaction reduces ROS, 
TNFα, and IL6 production by macrophages and limits transendothelial migration of monocytes, thereby improving EAE in mice and rats.
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CD40 monoclonal antibody in its parent murine form (mu5D12). 
mu5D12 mAb treatment interfered with development of clinical 
symptoms, even when mu5D12 mAb was given several weeks 
after T cell priming. In vivo localization shows that in addition 
to entering the secondary lymphoid organs, the mu5D12 mAb 
also enters the perivascular spaces of the CNS and to a smaller 
extent penetrates in the brain parenchyma. Therefore, anti-CD40 
can inhibit activation of primary and secondary antigen-specific 
T cells and B cells in both the secondary lymphoid organs and 
CNS lesions. The activity in secondary lymphoid organs is 
important since pathogenic T cells are continuously activated in 
the periphery during established EAE (21). Supporting this data, 
serial MRI demonstrated that ch5D12 treatment prevented the 
expansion of existing white matter lesions (99).
Combination Therapy of CD40–CD40L 
Blockade and Other Disease Modifying 
Agents
Blocking CD40–CD40L has been proven to be effective in 
reducing EAE, as described above. Disruption of CD40–CD40L 
interaction blocks activation of autoantigen-specific T cells and 
decreased leukocyte infiltration into the CNS. Therefore, it would 
be interesting to restore self-tolerance by enhancing Tregs in 
addition to the inhibition of the proinflammatory mechanisms. 
To achieve this, we should block multiple costimulatory dyads 
simultaneously to further increase the efficiency of the treatment. 
In the oncology field it has already been shown that immune 
checkpoint inhibitor combination therapy results in better out-
comes compared to the use of a single immune checkpoint inhibi-
tor, an example is the combination of nivolumab (anti-PD-1) and 
ipilimumab (anti-CTLA-4) (100).
Inflammatory cytokine production by astrocytes is induced 
upon activation by the CD40–CD40L interaction in a mast 
cell coculture. These cytokines re-activate astrocytes leading 
to increased release of cytokines that contribute to aggravating 
EAE development. Pretreatment with a combination of anti-
CD40 antibody and the Rac inhibitor 8-hydroxydeoxyguanosine 
(8-oxo-dG) decreased the EAE induced TNFR1 expression and 
colocalization of TNFR1 and astrocytes in the brain. This com-
bination therapy was able to decrease the clinical scores further 
than one of the treatments alone (69). Moreover, analysis of EAE 
brain tissues show that anti-CD40 Ab and 8-oxo-dG treatment 
enhanced the number of Treg cells, increased OX40 expression, 
and increased production of cytokines associated with Treg cells 
and their suppressive function (101).
Treatment of EAE with a combination of the CD40L 
antagonistic MR1 antibody and CTLA4Ig, blocking the CD28-B7 
interaction, provides additive protection in mice compared to 
single treatment, particularly in case of delayed administration. 
After treatment with the Anti-CD40L and CTLA4Ig combina-
tion mononuclear cell infiltrates were absent in the CNS, and in 
lymph nodes combination treatment is associated with a strong 
reduction in proliferation of primed T cells. According to these 
results, CD28 and CD40L might deliver different costimulatory 
signals for complete T cell activation, although there probably is 
8Aarts et al. The CD40–CD40L Dyad in MS
Frontiers in Immunology | www.frontiersin.org December 2017 | Volume 8 | Article 1791
an additional regulatory role for CD40L–CD40 interaction on B7 
expression. Blocking both the CD40–CD40L and the CD28-B7 
pathways in vivo possibly results in better suppression of patho-
genic immune responses (102).
Simultaneous knock-down of CD40 and the p19 subunit of 
IL-23 expression on bone marrow-derived DCs (BMDCs) by 
injection of double-transduced CD40+p19LV− BMDCs in EAE 
mice resulted in reduced clinical scores, significant decreased 
production of IL-17 and an increase in IL-10 compared with EAE 
mice treated with control lentiviral vector-DCs-(p19LV-DCs 
and CD40LV-DCs) (103). These studies show that combination 
therapies including blocking of CD40–CD40L interactions and 
an additional blockade can, by different mechanisms, more 
efficiently reduce EAE disease severity than anti-CD40L Ab or 
anti-CD40 Ab treatment alone.
Anti-CD40L Treatment in Clinical Trials
The experimental studies in rodents and primates highlighted 
the therapeutic potential of CD40–CD40L targeting strategies in 
MS and (15–21) paved the way for clinical studies. Anti-CD40L 
mAb IDEC-131 treatment was found to be successful in a phase 
I clinical trial with 15 MS patients, in this trial no relapses were 
observed in the complete cohort for at least 6 months. After this 
pilot, a phase II clinical trial with 46 MS patients was initiated 
in 2002. However, due to a severe case of thromboembolism in 
a similar trial with anti-CD40L mAb in Crohn’s disease patients 
(22), these trials were halted. The thromboembolic complications 
were caused by disruption of CD40L-αIIbβ3 interactions between 
platelets in arterial thrombi (13, 104, 105). For this reason, but 
also because of potential immunosuppressive adverse effects 
of antibody-mediated inhibition of CD40–CD40L, alternative 
strategies are required to exploit the therapeutic potential of 
CD40–CD40L inhibition in MS.
NOveL STRATeGieS TO TARGeT THe 
CD40–CD40L DYAD
One approach to reduce side-effects in treatment of EAE is 
specific delivery of drugs to CD40L positive T  cells. Based 
on CD40L crystal structure and molecular docking studies, 
Ding et  al. designed a CD40L specific peptide ligand (A25). 
The peptide A25 was conjugated on the surface of liposomes 
and capable of facilitating specific liposomal drug delivery to 
CD40L+ cells. CD40L+ cell ratios in EAE mice were significantly 
reduced by the A25 modified liposome loaded with methotrex-
ate (MTX), a cytostatic drug, resulting in markedly reduced 
clinical scores (106).
Based on our recent findings, we propose that more specific 
downstream inhibition of the CD40L–CD40 dyad may be another 
approach to overcome the current limitations. Using mice 
specifically lacking CD40-TRAF6 or CD40-TRAF2/3/5 interac-
tions, we showed that only CD40-TRAF6-deficient mice had a 
skewing in the immune response toward an anti-inflammatory 
profile and were protected against atherosclerosis (107). Based 
on these results, we developed small molecule inhibitors (SMIs) 
that efficiently and specifically block CD40-TRAF6 interactions 
and leave CD40-TRAF2/3/5 interactions intact (108). These SMIs 
are able to reduce peritonitis, sepsis, obesity-associated adipose 
tissue inflammation, and diabetes (108–111). Using an in vitro 
model for (neuro-) inflammation, we were able to show that SMI 
6877002 skews the phenotype of human monocytes toward a less 
inflammatory profile with reduced monocyte trans-endothelial 
migration capacity across brain ECs in vitro (23). Furthermore, 
upon SMI treatment EAE disease severity was reduced in Lewis 
rats, but not mice. However, in both models the SMI-treated 
animals had reduced levels of CNS-infiltrated monocyte-derived 
macrophages, but not T  cells (23). The experiments with SMI 
6877002 in EAE illustrate the therapeutic potential of CD40-
TRAF6 targeting strategies (Figures  2B,C), with the ability to 
reduce monocyte recruitment and macrophage activation in the 
CNS and this approach could potentially be used as a cotreatment 
to ameliorate MS.
CONCLUSiON AND FUTURe DiReCTiONS
This review emphasizes that besides the classical adaptive immu-
nity-related CD40L–CD40 signaling, this dyad has an essential 
role in the establishment and pathogenesis of MS in multiple 
ways. In particular, CD40 and CD40L are widely expressed on 
both resident and CNS-infiltrated cells in MS lesions and CD40 
gene SNPs associate with MS incidence. There are several treat-
ments available for RRMS, but additional therapeutic targets 
are still necessary, especially for progressive MS. Progressive 
MS is characterized more by nerve degeneration rather than 
inflammation. Monocyte-derived macrophages play an essential 
role in demyelination. In MS patients increased expression of 
CD40 on peripheral monocytes, and high expression of CD40 
on myelin-loaded macrophages in MS lesions was observed. 
Using EAE as a model for MS, inhibition of the CD40–CD40L 
dyad has found to be an effective strategy to reduce the onset and 
development of EAE in rodent and primates. However, treatment 
with anti-CD40/CD40L mAb resulted in unforeseen thrombo-
embolic side effects in human clinical trials, and bears the risk 
of immune suppression, which hampered further development 
of this strategy. Nevertheless, novel insights regarding treatment 
with combinations of immune checkpoint regulators, the use of 
nanoparticles, and the pivotal CD40L–CD40–TRAF signaling 
pathway in inflammatory diseases have revived the therapeutic 
potential of the CD40–CD40L dyad. These novel approaches 
are examples that the current limitations of long-term CD40 
and CD40L inhibition in MS and other inflammatory diseases 
can be overcome. CD40–CD40L plays an important role in the 
pathogenesis of MS and research has proven that this dyad is an 
important therapeutic target for treatment of MS.
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